“…A variety of alternative antiscarring strategies (Table 1), such as photodynamic therapy,101–104 saratin (Merck KGaA),105,106 sonepcizumab (Lpath, Inc., San Diego, CA, USA),107 doxycycline (Pfizer Inc.),108 pirfenidone (InterMune, Brisbane, CA, USA),109,110 tacrolimus (Astellas Pharma Inc., Tokyo, Japan),111 and octreotide (Novartis),111 have also shown promising results by improving the outcome of surgery in a standard rabbit model. Although many agents have been evaluated in preclinical models for glaucoma filtration surgery, few have been found to be beneficial in large prospective comparative clinical trials and none have replaced mitomycin C or 5-fluorouracil in clinical practice so far.…”